Behçet disease (CNS manifestations)

Changed by Craig Hacking, 18 Aug 2021

Updates to Article Attributes

Body was changed:

CNS manifestations of Behçet disease, also known as neuro-Behçet disease, corresponds to the neurological involvement of the systemic vasculitis Behçet disease and has a variety of manifestations. 

For a discussion of the disease, in general, please refer to Behçet disease article. 

Epidemiology

CNS involvement is seen in 4-49% of patients with systemic Behçet disease and has the same predilection of patients of middle eastern and Japanese descent 1

Clinical presentation

In the vast majority of cases, ulcerative lesions preceded neurological involvement, aiding in the diagnosis. In 3% of cases, central nervous system manifestations occur first, making diagnosis significantly more challenging 1. Signs and symptoms include 1:

  • headaches
  • sensory disturbances
  • personality changes
  • dysarthria
  • cerebellar signs

Pathology

Neuro-Behçet disease, depending on the stage or degree of the inflammation, shows perivascular infiltration of leukocytes and microglia, degeneration of oligodendroglia, and perivascular softening or necrosis 3.

Radiographic features

Neuro-Behçet disease has a wide variety of manifestations in the central nervous system, including 1

Meningoencephalitis and cerebral vein thrombosis are discussed separately in general articles related to these conditions. 

MRI

Lesions in neuro-Behçet disease typically involve 1,3, in order of preference: 

Lesions in neuro-Behçet disease typically demonstrate the following signal characteristics 1:

  • T1: usually hypointense
  • T2:
    • usually hyperintense
    • associated with vasogenic oedema
    • in acute phase, lesions cause mass effect 
  • T1 C+ (Gd): typically moderate patchy enhancement
  • DWI: isointense to slightly hyperintense
  • MRS: drop in NAA, with elevated lipid and choline/creatine ratio 4

Treatment and prognosis

  • corticosteroids: intravenous methylprednisolone infusion then oral prednisone 
  • immunosuppression: azathioprine, methotrexate, and TNFα inhibitors 2

Differential diagnosis

General imaging differential considerations include

Consider other causes of T2 hyperintensity of the basal ganglia

  • -<li>immunosuppression: azathioprine, methotrexate, and TNFα inhibitors <sup>2 </sup>
  • +<li>
  • +<a href="/articles/immunosuppression">immunosuppression</a>: azathioprine, methotrexate, and TNFα inhibitors <sup>2 </sup>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.